Company Encyclopedia
View More
name
Ovid Therap
OVID.US
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H.
1.946 T
OVID.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking137/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-59.30%E
    • Profit Margin-549.62%E
    • Gross Margin100.00%A
  • Growth ScoreB
    • Revenue YoY945.89%A
    • Net Profit YoY-13.55%D
    • Total Assets YoY-37.80%E
    • Net Assets YoY-41.41%E
  • Cash ScoreB
    • Cash Flow Margin-18.43%D
    • OCF YoY945.89%A
  • Operating ScoreE
    • Turnover0.08E
  • Debt ScoreB
    • Gearing Ratio29.99%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ovid Therapeutics Names Dr. Petra Kaufmann as Chief Medical Officer

    Ovid Therapeutics Inc. has appointed Dr. Petra Kaufmann as Chief Medical Officer to oversee clinical, medical, and regulatory strategy for its brain disorder therapies. Dr. Kaufmann brings experience from Vigil Neuroscience, Affinia Therapeutics, Novartis Gene Therapies, and the National Institutes of Health.

    Reuters·
    US
    OVID
    +2.53%
    Reuters·
    US
    OVID
    +2.53%

    Equities Analysts Issue Forecasts for OVID Q4 Earnings

    Leerink Partners issued Q4 2025 EPS estimates for Ovid Therapeutics, predicting ($0.10) per share. They maintain a "Strong-Buy" rating, with a $5.00 price target. Ovid's current full-year EPS estimate is ($0.40). Other analysts have mixed ratings, with an average "Buy" rating and a $3.92 price target. Ovid's stock opened at $1.32, with a market cap of $94 million. Institutional investors hold 72.24% of shares. Ovid develops treatments for neurological disorders, with several drugs in clinical trials.

    Market Beat·
    US
    OVID
    +2.53%
    Market Beat·
    US
    OVID
    +2.53%

    Ovid Therapeutics (NASDAQ:OVID) Stock Rating Lowered by Wall Street Zen

    Wall Street Zen downgraded Ovid Therapeutics from a "hold" to a "sell" rating. Despite this, Ovid has mixed ratings from other analysts, with some maintaining "buy" ratings. The stock opened at $1.31, with a market cap of $92.93 million. Institutional investors hold 72.24% of the stock. Ovid is developing treatments for neurological disorders, with several drugs in clinical trials.

    Market Beat·
    US
    OVID
    +2.53%
    Market Beat·
    US
    OVID
    +2.53%

    Ovid Therapeutics Showcases Neurotherapeutics Pipeline Targeting Drug-Resistant Seizures and Neural Hyperexcitability

    Ovid Therapeutics Inc. updated its neurotherapeutics pipeline targeting neural hyperexcitability. Key programs include OV329 for drug-resistant seizures, with Phase 2a starting in Q2 2026, and OV350 IV, with Phase 1 results expected in Q4 2025. Other candidates are OV4071 for psychosis and OV4041 for anxiety and Rett syndrome, with studies planned for 2026. The company has a cash runway into H2 2028.

    Reuters·
    US
    OVID
    +2.53%
    Reuters·
    US
    OVID
    +2.53%

    BTIG Keeps Their Buy Rating on Ovid Therapeutics (OVID)

    BTIG's Thomas Shrader maintains a Buy rating on Ovid Therapeutics with a $4.00 price target, while Oppenheimer downgrades it to Buy with a $7.00 target. Ovid's shares closed at $1.20, with a consensus price target of $4.50, indicating a 275% upside. Shrader, a 3-star analyst, covers the Healthcare sector.

    Tip Ranks·
    US
    OVID
    +2.53%
    Tip Ranks·
    US
    OVID
    +2.53%
    © 2025 Longbridge｜Disclaimer